Irvine, Calif., Nov. 9, 2009 – The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries – a finding that could expand the clinical trial to include people with cervical damage.
In January, the U.S. Food & Drug Administration gave Geron Corp. of Menlo Park, Calif., permission to test the UC Irvine treatment in individuals with thoracic spinal cord injuries, which occur below the neck. However, trying it in those with cervical damage wasn't approved because preclinical testing with rats hadn't been completed.
Results of the cervical study currently appear online in the journal Stem Cells. UCI scientist Hans Keirstead hopes the data will prompt the FDA to authorize clinical testing of the treatment in people with both types of spinal cord damage. About 52 percent of spinal cord injuries are cervical and 48 percent thoracic.
"People with cervical damage often have lost or impaired limb movement and bowel, bladder or sexual function, and currently there's no effective treatment. It's a challenging existence," said Keirstead, a primary author of the study. "What our therapy did to injured rodents is phenomenal. If we see even a fraction of that benefit in humans, it will be nothing short of a home run."
A week after test rats with 100 percent walking ability suffered neck spinal cord injuries, some received the stem cell treatment. The walking ability of those that didn't degraded to 38 percent. Treated rats' ability, however, was restored to 97 percent.
UCI's therapy utilizes human embryonic stem cells destined to become spinal cord cells called oligodendrocytes. These are the building blocks of myelin, the biological insulation for nerve fibers that's critical to proper functioning of the central nervous system. When myelin is stripped away through injury or disease, paralysis can occur.
Lead author and doctoral student Jason Sharp, Keirstead and colleagues discovered that the stem cells not only rebuilt myelin but prevented tissue death and triggered nerve fiber regrowth. They also suppressed the immune response, causing an increase in anti-inflammatory molecules.
"The transplant created a healing environment in the spinal cord," said Keirstead, who is co-director of the Sue & Bill Gross Stem Cell Research Center and on the faculty of the Reeve-Irvine Research Center – named for late actor Christopher Reeve, who became a quadriplegic after a cervical spinal cord injury.
In addition to Keirstead and Sharp, Jennifer Frame, Monica Siegenthaler and Dr. Gabriel Nistor of UCI worked on the study, which was supported by Geron Corp., a University of California Discovery Grant, the Roman Reed Spinal Cord Injury Research Fund of California, Research for Cure, and individual donations to the Reeve-Irvine Research Center.
About the University of California, Irvine: Founded in 1965, UCI is a top-ranked university dedicated to research, scholarship and community service. Led by Chancellor Michael Drake since 2005, UCI is among the fastest-growing University of California campuses, with more than 27,000 undergraduate and graduate students, 1,100 faculty and 9,200 staff. The top employer in dynamic Orange County, UCI contributes an annual economic impact of $4.2 billion. For more UCI news, visit www.today.uci.edu.
News Radio: UCI maintains on campus an ISDN line for conducting interviews with its faculty and experts. Use of this line is available for a fee to radio news programs/stations that wish to interview UCI faculty and experts. Use of the ISDN line is subject to availability and approval by the university.
Contact:
Jennifer Fitzenberger
949-824-3969
jfitzen@uci.edu
UCI maintains an online directory of faculty available as experts to the media. To access, visit www.today.uci.edu/experts. For UCI breaking news, visit www.zotwire.uci.edu.
Journal
Stem Cells